CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients.

ABSTRACT:

Background & aims

The WHO declared to eliminate hepatitis B virus (HBV) by 2030. However, an increasing number of patients are presenting with low-level viremia (LLV) with the widespread use of antiviral medications. The diagnostic efficiency and coverage area of HBV infection are low. Hence, this study intended to drive the HBV infection detection to effectively adaptable for any small to medium-sized laboratory or field survey.

Methods

We established, optimized, and evaluated a colloidal gold test strip for detection of HBV DNA based on CRISPR/Cas13a combined with recombinase-aided amplification (RAA) technology. Furthermore, 180 HBV-infected patients (including patients with different viral loads, LLV patients and dynamic plasma samples of patients on antiviral therapy) w

SUBMITTER: Tian Y 

PROVIDER: S-EPMC9946317 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature